NCT06605105
ClinicalTrials.gov
- Trial ID
- T-ctgov-NCT06605105
- Registry
- ClinicalTrials.gov
- NCT number
- NCT06605105
- Asset
- HLP003
- Sponsor, as registered
- Cybin IRL Limited
- Phase
- PHASE3
- Indication
- Major Depressive Disorder
- Status
- ENROLLING_BY_INVITATION
- Start date
- 2025-07-18
- Primary completion
- 2028-06-06
- Registered countries
- Australia, Greece, Poland, United Kingdom, United States
- Sites
- 49
The sponsor's registered location list, which states intent rather than approval.
clinicaltrials.govctgov registryverified 2026-10-13
Notes on the record
Supersedes the T-ctgov-NCT06605105 row verified 2026-08-31. Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site, not once per country. Read 2026-10-13 18:29 Berlin; lastUpdatePostDate 2026-09-25; primary completion type ESTIMATED. Location entries by country: United States 42, Australia 3, Greece 2, Poland 1, United Kingdom 1. Changed: primary_completion_date 2028-03-15 -> 2028-06-06, countries Australia;United States -> Australia;Greece;Poland;United Kingdom;United States, site_count 33 -> 49. Proposed as T1 in digests/2026-10-12-triage.md (read 2026-10-11); re-read live 2026-10-13, no field differs from that read.
Company
Through HLP003: Helus Pharma
Cited in
Issues quoting NCT06605105 in their own text.